Channel Therapeutics CORP 8-K filings

Chromocell Therapeutics has announced the launch of its eye pain treatment program and the hiring of Dr. Simon Chandler to lead the initiative.

Chromocell Therapeutics has officially appointed Francis Knuettel II as its permanent Chief Executive Officer, removing his interim status held since July 2023.

Chromocell Therapeutics presented an update on its non-opioid pain treatment pipeline, including clinical trials for its lead compound CC8464, at the Sidoti Small Cap Conference.

Chromocell Therapeutics Corporation successfully closed its initial public offering, raising approximately $6.6 million in gross proceeds.